Skip to main content
PCVX logo

Vaxcyte, Inc. (PCVX) Stock: Price, Forecast & Analyst Target

Vaxcyte, Inc. (PCVX) — MoonshotScore 51/100 (Fair band), calculated Nov 18, 2026. Price $58.36 (-0.27%), as of the Nov 19, 2026 trading session; market cap $9.24B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 7.15× (cash as of Sep 30, 2026) · expected results Feb 23, 2027

$58.36 −$0.16 (-0.27%) Market Cap $9.24B

Vaxcyte, Inc. · PCVX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Vaxcyte is a clinical-stage vaccine developer pursuing protein-based vaccines against bacterial disease, led by a pneumococcal conjugate program rather than a commercial product franchise. Its case depends on whether clinical progress can outrun escalating research spending and cash consumption while reported revenue remains absent.

Price as of Nov 19, 2026

Key Statistics

51 of 100

MoonshotScore v2 · Vaxcyte (PCVX)

Fair
Business Quality Average (40)
Financial Safety Okay (48)
Valuation Full (46)
Growth Durability Shrinking (8)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Strong price action running well ahead of the business — stalling growth underneath; a move to treat with suspicion, not chase. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • Altman Z 9.00 · Piotroski F 0
  • ROE -42.7% · ROA -25.0% · current ratio 4.56

Holding back: soft growth

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PCVX (57 recorded, newest six shown)
RecordedScoreBand
54Fair
53Fair
53Fair
53Fair
51Fair
51Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$58.36
Change on the day-0.27%
52-week range$42.40–$90.75
Market capitalisation$9.24B—
Shares traded on the day981.1K
Beta (volatility vs the S&P 500)1.29

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $42, high $71, latest $58. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $71 $42 high $71 Feb 24, 2026 · Earnings results · reported below the recorded estimate · close $621May 6, 2026 · Earnings results · reported below the recorded estimate · close $532Aug 5, 2026 · Earnings results · reported above the recorded estimate · close $583Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $644 Oct 17, 2025 Nov 19, 2026 · $58 $42Oct 17, 2025$45Oct 31, 2025$49Nov 14, 2025$50Nov 28, 2025$45Dec 12, 2025$47Dec 26, 2025$46Jan 9, 2026$53Jan 23, 2026$56Feb 6, 2026$59Feb 20, 2026$59Mar 6, 2026$55Mar 20, 2026$58Apr 2, 2026$62Apr 17, 2026$57May 1, 2026$52May 15, 2026$51May 29, 2026$47Jun 12, 2026$57Jun 26, 2026$58Jul 10, 2026$55Jul 24, 2026$58Aug 7, 2026$63Aug 21, 2026$61Sep 4, 2026$58Sep 18, 2026$56Oct 2, 2026$64Oct 16, 2026$62Oct 30, 2026$63Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Vaxcyte (PCVX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Neutral
Valuation Neutral
Growth Durability Negative
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Vaxcyte (PCVX), and what does it report?

Short answer · as of

Vaxcyte develops vaccine candidates intended to prevent or manage bacterial infections, including pneumococcal disease, emergent strains associated with antimicrobial resistance, Group A Streptococcus and periodontitis.

Investors are funding a development portfolio whose value rests on clinical advancement, not current vaccine sales.

The income statement therefore measures the cost of advancing that portfolio. Reported revenue has remained absent, while research and development dominates operating expense and drives recurring losses.

2 · Latest results

What do the latest results show for Vaxcyte (PCVX)?

The latest period showed research spending retreating from the preceding peak, accompanied by narrower operating and net losses. The earnings loss also came in better than the prevailing estimate, reversing a run of unfavorable comparisons.

Cash performance moved the other way: operating cash outflow reached its heaviest level in the reported series, while cash and short-term investments declined. Vaxcyte’s stated focus remains the advancement of protein-based bacterial vaccines; that development agenda supplies the strategic context for a broader pattern of rising research expense and widening annual losses without revenue.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · R&D
$270.33M Sep 30, 2026
Latest quarter · SG&A
$37.95M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$308.27M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not available$270.33M$37.95M−$308.27M
Jun 30, 2026Not available$267.85M$34.92M−$302.78M
Mar 31, 2026Not available$312.78M$33.07M−$345.85M
Dec 31, 2025Not available$242.06M$32.22M−$274.28M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue estimate
$12.50M Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026Not available$12.50M−$1.9900−$2.1100
Aug 5, 2026Not available$12.50M−$1.9700−$2.0600
May 6, 2026Not available$12.50M−$2.3000−$1.7775
Feb 24, 2026Not available$18.75M−$1.8000−$1.5297
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$0-$297M-$1.99 (diluted)
Q2 FY2026$0-$284M-$1.97 (diluted)
Q1 FY2026$0-$321M-$2.30 (diluted)
Q4 FY2025$0-$247M-$1.81 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Vaxcyte (PCVX)?

Short answer

Cash and short-term investments were $1.29B at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$224.08M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Liquidity is the principal financial strength. Cash and investments substantially exceed debt and total liabilities, leverage is low, and short-term liquidity ratios indicate ample coverage of current obligations.

That protection is being consumed rather than replenished by operations. Cash has declined across the reported window, operating cash flow remains deeply negative, and the latest outflow accelerated sharply; clinical delays, larger development programs or disappointing trial progress would therefore make the remaining liquidity carry more of the burden.

Data-derived red flags

  • Negative return on equity (-42.7%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$224.08M Sep 30, 2026
Previous quarter · operating cash flow
−$513.10M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$224.08M−$4.96M
Jun 30, 2026−$513.10M−$19.37M
Mar 31, 2026−$280.62M−$14.79M
Dec 31, 2025−$224.83M$5.57M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Vaxcyte (PCVX)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

The scheduled earnings release should be read through research expense, operating cash use and the movement in cash and investments. A narrower accounting loss would be less reassuring if cash outflow remained elevated.

Consensus expectations introduce revenue despite a long record of none. Any recognized revenue should be examined for its source and durability before it is treated as evidence of vaccine commercialization, while subsequent filings should be checked for changes in the pace or scope of the pneumococcal and broader bacterial vaccine programs.

5 · Peer comparison

How does Vaxcyte compare with its peers?

Short answer

Vaxcyte's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Vaxcyte is better compared with precommercial vaccine developers than with established vaccine manufacturers: its reported economics are research expense, losses and cash deployment rather than product volume and margins. Its distinguishing focus is a lead pneumococcal conjugate program supported by candidates addressing emergent bacterial strains, Group A Streptococcus and periodontitis.

The balance sheet gives that portfolio meaningful development capacity, but market value still exceeds net cash by a wide margin. The valuation therefore reflects expectations for the vaccine programs rather than an operating business already supported by sales.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Named competitor$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Named competitor$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
Vaxcyte (PCVX) — this page$58.36$9.24B51

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$120.00 – $125.00
Consensus target
$122.33
Median target
$122.00

Consensus record · Captured .

Measured against a quoted price of $58.36 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026

Transactions
97
Identified insiders
9
Purchases
0
Sales
46
Other transactions
51

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
378 Period end Sep 30, 2026
Previous quarter · holders
353 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Fmr LLC22,480,592
Janus Henderson Group Ltd.17,919,449
T. Rowe Price Investment Management, INC.14,300,004
Blackrock, INC.12,179,969
Ra Capital Management, L.P.11,474,599

Tracked investors

Which of the 16 named investors we follow held PCVX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PCVX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Vaxcyte (PCVX)?

Read these with our analysis →

Vaxcyte Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Is Vaxcyte already earning revenue from its pneumococcal vaccine program?

Reported revenue remains absent, so current financial statements reflect vaccine development costs rather than commercial pneumococcal sales.

How does VAX-XP fit alongside Vaxcyte’s lead pneumococcal program?

VAX-XP extends the pipeline toward emergent bacterial strains and antimicrobial resistance, broadening the company’s scientific exposure beyond the lead pneumococcal candidate.

What does VAX-PG add to Vaxcyte’s vaccine portfolio?

VAX-PG targets the principal pathogen associated with periodontitis, giving Vaxcyte a bacterial vaccine program aimed at oral disease alongside its systemic infectious-disease candidates.

Can Vaxcyte fund vaccine development from product sales?

Product revenue is not currently supporting development. Funding capacity instead rests on cash and investments that exceed debt, although negative operating cash flow and the decline in cash make spending discipline increasingly consequential.

What is the PCVX stock price today?

The last price recorded for Vaxcyte, Inc. (PCVX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PCVX price target?

The analyst consensus price target for Vaxcyte, Inc. (PCVX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 67 figures on this page — 1 from SEC filings and earnings calls, 60 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • 1. What is Vaxcyte (PCVX), and what does it report?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Vaxcyte (PCVX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Reported versus estimated, last 8 quarters; Business description
  • 3. What are the financial strengths and risks for Vaxcyte (PCVX)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Business description
  • 4. What should you watch next at Vaxcyte (PCVX)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Most recent periodic reports; Recent SEC filings; Business description
  • 5. How does Vaxcyte compare with its peers?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt; Cash against market value; Trailing twelve-month ratio set
  • FAQ: Is Vaxcyte already earning revenue from its pneumococcal vaccine program?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: How does VAX-XP fit alongside Vaxcyte’s lead pneumococcal program?: Business description
  • FAQ: What does VAX-PG add to Vaxcyte’s vaccine portfolio?: Business description
  • FAQ: Can Vaxcyte fund vaccine development from product sales?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold PCVX

Funds in our ETF coverage that list PCVX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
State Street SPDR S&P Biotech ETF (XBI)1.73%
iShares Russell 2000 Value ETF (IWN)0.51%